Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Raw Materials (2016 - 2020)

Historic Raw Materials for United Therapeutics (UTHR) over the last 11 years, with Q1 2020 value amounting to $20.1 million.

  • United Therapeutics' Raw Materials fell 986.55% to $20.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $20.1 million, marking a year-over-year decrease of 986.55%. This contributed to the annual value of $21.1 million for FY2019, which is 1316.87% down from last year.
  • As of Q1 2020, United Therapeutics' Raw Materials stood at $20.1 million, which was down 986.55% from $21.1 million recorded in Q4 2019.
  • United Therapeutics' Raw Materials' 5-year high stood at $29.1 million during Q2 2017, with a 5-year trough of $19.3 million in Q3 2019.
  • For the 5-year period, United Therapeutics' Raw Materials averaged around $24.4 million, with its median value being $24.8 million (2016).
  • In the last 5 years, United Therapeutics' Raw Materials skyrocketed by 1733.87% in 2017 and then plummeted by 2576.92% in 2019.
  • United Therapeutics' Raw Materials (Quarter) stood at $25.4 million in 2016, then grew by 9.84% to $27.9 million in 2017, then decreased by 12.9% to $24.3 million in 2018, then fell by 13.17% to $21.1 million in 2019, then fell by 4.74% to $20.1 million in 2020.
  • Its Raw Materials was $20.1 million in Q1 2020, compared to $21.1 million in Q4 2019 and $19.3 million in Q3 2019.